I V Bogolyubova

Hospital for War Veterans, Saint Petersburg, Russia.

1 publication 2025 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does I V Bogolyubova research?

I V Bogolyubova studies the effects of a medication called Revelise, which is used to treat ischemic strokes. Ischemic strokes happen when blood flow to the brain is blocked, often requiring timely medical intervention. Their research primarily involves understanding how effective this treatment is after it’s administered in hospitals and how it impacts patients’ recovery. The studies evaluate the medication’s ability to reduce disabilities related to strokes, especially among older adults and those who may not be in perfect health.

Key findings

  • In a study involving 2,202 patients with ischemic strokes, 49.9% experienced good outcomes at discharge.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%.
  • Revelise demonstrated effectiveness in reducing stroke-related disabilities in various patient demographics, including older adults.

Frequently asked questions

Does Dr. Bogolyubova study ischemic strokes?
Yes, Dr. Bogolyubova focuses on treating ischemic strokes with the medication Revelise.
What treatments has Dr. Bogolyubova researched?
Dr. Bogolyubova has researched the use of Revelise (alteplase) for treating ischemic strokes.
Is Dr. Bogolyubova's work relevant to older stroke patients?
Yes, their research specifically includes findings on the effectiveness of Revelise in older patients.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.